MAZE Form 4: Director Richard Scheller disposes of all reported shares

Rhea-AI Filing Summary

Maze Therapeutics director Richard H. Scheller reported a sale of company stock on September 15, 2025. The filing shows 20,744 shares of Maze common stock were disposed of in multiple transactions at a weighted average price of $22.3696 per share, with individual trade prices ranging from $22.14 to $22.585. After the reported sale the reporting person beneficially owned 0 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on September 16, 2025. The filer is identified as a director of Maze Therapeutics and the transaction is recorded as a non-derivative sale of common stock.

Positive

• None.

Negative

• Director disposed of all reported beneficial holdings: 20,744 shares were sold and the reporting person now reports 0 shares beneficially owned.
• Complete sale disclosed without explanatory context: the filing provides no reason for the sale, limiting investors' ability to assess motives.

Insights

Corporate Governance Expert

TL;DR: A company director sold all reported common stock holdings in a single disclosed transaction.

The Form 4 discloses that Director Richard H. Scheller sold 20,744 shares of Maze Therapeutics common stock on 09/15/2025 at a weighted average price of $22.3696, reducing reported beneficial ownership to zero. From a governance perspective, director sales can reflect personal liquidity needs or portfolio rebalancing; the filing itself provides no explanation. The disclosure is timely and complies with Section 16 requirements, including a footnote that the sale occurred across multiple executions at prices between $22.14 and $22.585.

Securities Analyst

TL;DR: Material transaction size relative to prior holdings is unknown; the filing confirms complete disposition.

For investors monitoring insider activity, the key facts are the sale quantity (20,744 shares), the weighted average price ($22.3696), the price range ($22.14–$22.585), and that post-transaction beneficial ownership is reported as zero. The Form 4 contains no information on prior holdings, timing rationale, or related party transactions, so impact assessment is limited to the factual sale disclosure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

SCHELLER RICHARD H

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2025		S		20,744	D	$22.3696(1)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.14 to $22.585, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Courtney Phillips, as attorney-in-fact	09/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Maze Therapeutics (MAZE) report on Form 4?

Director Richard H. Scheller sold 20,744 shares of Maze common stock on 09/15/2025, reported on Form 4.

At what price were the MAZE shares sold by the reporting person?

Weighted average price $22.3696, with individual sale prices ranging from $22.14 to $22.585.

How many Maze shares does the reporting person own after the transaction?

0 shares beneficially owned following the reported sale.

Who filed the Form 4 on behalf of the reporting person?

The Form 4 was signed by Courtney Phillips as attorney-in-fact on 09/16/2025.

Does the Form 4 indicate any derivative transactions for MAZE?

No derivative securities are reported; the filing records a non-derivative sale of common stock only.